57017-95-5

Basic information

• Product Name: methyl 3-chloro-4-hydroxyphenylacetate
• Synonyms: methyl 3-chloro-4-hydroxyphenylacetate;3-Chloro-4-hydroxybenzeneacetic acid methyl ester;Einecs 260-514-8;METHYL 2-(3-CHLORO-4-HYDROXYPHENYL)ACETATE
• CAS NO: 57017-95-5
• Molecular Formula: C₉H₉ClO₃
• Molecular Weight: 200.61896
• EINECS: 260-514-8
• Mol File: 57017-95-5.mol
• Article Data: 32

Chemical Properties

• Boiling Point: 286.7°C at 760 mmHg
• Flash Point: 127.2°C
• Appearance: /
• Density: 1.314g/cm³
• Vapor Pressure: 0.00151mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: methyl 3-chloro-4-hydroxyphenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-chloro-4-hydroxyphenylacetate(57017-95-5)
• EPA Substance Registry System: methyl 3-chloro-4-hydroxyphenylacetate(57017-95-5)

Safety Data

• Hazardous Substances Data: 57017-95-5(Hazardous Substances Data)

Usage

Description

Methyl 3-chloro-4-hydroxyphenylacetate is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by the presence of a chloro substituent at the 3-position and a hydroxyl group at the 4-position on a phenyl ring, with an ester linkage to a methyl group.

Uses

Used in Pharmaceutical Industry:
Methyl 3-chloro-4-hydroxyphenylacetate is used as a reagent for the preparation of benzenesulfonamide derivatives, which are important in the development of ATP citrate lyase inhibitors. These inhibitors play a crucial role in targeting metabolic pathways in cancer cells, making them potential candidates for cancer treatment and therapy.

InChI:InChI=1/C9H9ClO3/c1-13-9(12)5-6-2-3-8(11)7(10)4-6/h2-4,11H,5H2,1H3

Upstream product

• 33697-81-3 (3-chloro-4-hydroxy-phenyl)-acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 766-51-8 2-Chloroanisole 
• 13719-57-8 3-chloro-4-methoxybenzyl chloride 
• 67-56-1 methanol 
• 141805-68-7 N-(3-Chloro-4-hydroxyphenylacetyl)fumarate 
• 7569-58-6 2-(3-chloro-4-methoxyphenyl)acetonitrile 

Downstream Products

• 60736-80-3 3-chloro-4-(4'-ethylbenzyloxy)-phenylacetic acid 
• 496856-44-1 methyl 2-(3-chloro-4-(triuoromethylsulfonyloxy)phenyl)acetate 
• 1147391-88-5 methyl 2-(3-chloro-4-(4-methoxybenzyloxy)phenyl)acetate 
• 91361-78-3 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 
• 91361-79-4 3-chloro-4-sulphanyl-phenylacetic acid methyl ester 
• 890137-68-5 [4-(4,4''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-ylmethylsulfanyl)-3-chloro-phenyl]-acetic acid methyl ester 
• 890137-67-4 [4-(4,4''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-ylmethoxy)-3-chloro-phenyl]-acetic acid methyl ester 
• 905991-71-1 (3-chloro-4-{3-[(5-[1,2]dithiolan-3-yl-pentanoyl)-methyl-amino]-propoxy}-phenyl)-acetic acid methyl ester 
• 905991-67-5 (3-chloro-4-{2-[(5-[1,2]dithiolan-3-yl-pentanoyl)-methyl-amino]-ethoxy}-phenyl)-acetic acid methyl ester 
• 870289-05-7 [3-chloro-4-(3,5-dibromobenzylsulfanyl)phenyl]acetic acid methyl ester 
• 1009101-96-5 methyl 2-(4-(4-((4-chlorophenethyl)carbamoyl)-2-nitrophenoxy)-3-chlorophenyl)acetate 
• 905991-57-3 methyl (4-{3-[(tert-butoxycarbonyl)(methyl)amino]propoxy}-3-chlorophenyl)acetate 
• 905991-54-0 methyl (4-{2-[(tert-butoxycarbonyl)(methyl)amino]ethoxy}-3-chlorophenyl)acetate 
• 870289-04-6 [3-chloro-4-(3,5-dibromobenzyloxy)phenyl]acetic acid methyl ester 

Relevant articles and documents

Design and synthesis of a screening library using the natural product scaffold 3-chloro-4-hydroxyphenylacetic acid

The fungal metabolite 3-chloro-4-hydroxyphenylacetic acid (1) was utilized in the generation of a unique drug-like screening library using parallel solution-phase synthesis. A 20-membered amide library (3-22) was generated by first converting 1 to methyl (3-chloro-4-hydroxyphenyl)acetate (2), then reacting this scaffold with a diverse series of primary amines via a solvent-free aminolysis procedure. The structures of the synthetic analogues (3-22) were elucidated by spectroscopic data analysis. The structures of compounds 8, 12, and 22 were confirmed by single X-ray crystallographic analysis. All compounds were evaluated for cytotoxicity against a human prostate cancer cell line (LNCaP) and for antiparasitic activity toward Trypanosoma brucei brucei and Plasmodium falciparum and showed no significant activity at 10 μM. The library was also tested for effects on the lipid content of LNCaP and PC-3 prostate cancer cells, and it was demonstrated that the fluorobenzyl analogues (12-14) significantly reduced cellular phospholipid and neutral lipid levels.

Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands

The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands

The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.